Related Experiment Video
Updated: Jun 24, 2026
Validated Immunochemical Assay for Comprehensive Determination of the Human Epidermal Growth Factor Receptor 2 Released from and Bound to Cells
Published on: May 9, 2025
KRAS status and epidermal growth factor receptor expression as determinants for anti-EGFR therapies in salivary gland
Regine Dahse1, Oliver Driemel, Stephan Schwarz
1Institute of Pathology, HELIOS Klinikum Erfurt, Germany. rdahse@erfurt.helios-kliniken.de
Abstract:
Salivary gland carcinomas (SGC) are rare cancers with poor prognosis and limited response to conventional chemotherapy. New strategies based on molecular targeted therapy are needed and the EGFR signaling cascade is considered a possible key pathway for therapeutic molecules. We have analyzed 65 SGC of the main histopathological types for the expression of EGFR and and the mutation status of its downstream effector KRAS. EGFR overexpression (+2, +3) has been identified by immunohistochemistry in 75.4%. KRAS mutation analysis was performed by direct genomic sequencing and revealed a KRAS wildtype in 98.5% except of one adenoid cystic carcinoma with a GGT-GAT transition at codon 12 (Gly12Asp). EGFR overexpression and KRAS wildtype are prerequisites for a successful anti-EGFR therapy. The results of this study plead in favor of further therapeutic trials with EGFR-targeting monoclonal antibodies in SGC.
Insights
Salivary gland carcinomas (SGC) show high Epidermal Growth Factor Receptor (EGFR) overexpression and mostly wildtype KRAS. This suggests SGC may respond to EGFR-targeted therapies.
Area of Science:
- Oncology
- Molecular Biology
- Cancer Research
Background:
- Salivary gland carcinomas (SGC) are rare malignancies with limited treatment options.
- The Epidermal Growth Factor Receptor (EGFR) signaling pathway is implicated in various cancers and presents a potential therapeutic target.
Purpose of the Study:
- To investigate the expression levels of EGFR and the mutation status of its downstream effector KRAS in SGC.
- To evaluate the potential of EGFR-targeted therapies for SGC based on molecular markers.
Main Methods:
- Immunohistochemistry was used to assess EGFR expression in 65 SGC samples.
- Direct genomic sequencing was employed to analyze KRAS mutation status in the same cohort.
Main Results:
- EGFR overexpression (grades +2, +3) was observed in 75.4% of SGC cases.
- A KRAS wildtype status was found in 98.5% of the samples, with only one case showing a KRAS mutation at codon 12.
Conclusions:
- The high prevalence of EGFR overexpression and KRAS wildtype status in SGC supports its role as a therapeutic target.
- These findings advocate for clinical trials investigating EGFR-targeting monoclonal antibodies in SGC treatment.
More Related Videos
15:05Deciphering the Structural Effects of Activating EGFR Somatic Mutations with Molecular Dynamics Simulation
Published on: May 20, 2020
09:38Establishing Dual Resistance to EGFR-TKI and MET-TKI in Lung Adenocarcinoma Cells In Vitro with a 2-step Dose-escalation Procedure
Published on: August 11, 2017
